Oral low-dose dexamethasone for androgen-independent prostate cancer patients

Komiya,Akira; Shimbo,Masaki; Suzuki,Hiroyoshi; Imamoto,Takashi; Kato,Tomonori; Fukasawa,Satoshi; Kamiya,Naoto; Naya,Yukio; Mori,Ikuo; Ichikawa,Tomohiko

doi:10.3892/ol_00000013

Oral low-dose dexamethasone for androgen-independent prostate cancer patients

Authors:
- Akira Komiya
- Masaki Shimbo
- Hiroyoshi Suzuki
- Takashi Imamoto
- Tomonori Kato
- Satoshi Fukasawa
- Naoto Kamiya
- Yukio Naya
- Ikuo Mori
- Tomohiko Ichikawa
View Affiliations

Affiliations: Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama 930-0194, Japan. komiya@med.u-toyama.ac.jp
Published online on: January 1, 2010 https://doi.org/10.3892/ol_00000013
Pages: 73-79

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We retrospectively evaluated the outcome of oral low-dose dexamethasone (DXM) therapy for androgen-independent prostate cancer (AIPC). Between January 1999 and April 2006, 99 consecutive patients with AIPC were enrolled in this study. The median patient age was 70 years (range 46-86), and the median pretreatment prostate-specific antigen (PSA) level was 243 ng/ml (range 8.2-29600). Median follow-up was 41.9 months (range 11.4-170.4). Upon biochemical failure, patients were treated with oral low-dose DXM. A total of 40 of the 99 cases (40.4%) showed a ≥50% decrease in serum PSA levels (PSA responders). Twenty-five cases (25.2%) showed a <50% decrease in PSA, and the remaining 34 cases (34.3%) had increased PSA levels (PSA non-responders). The median PSA progression-free survival was 3.0 (range 0-27) and 8.0 months (range 2-27) for the entire cohort and PSA responders, respectively. The PSA responders had a significantly increased survival (median 30.1 months) compared to the non-responders (median 8.8 months, P<0.001). Of the 34 patients who were under pain control for bone metastases before the administration of DXM, 23 (67.6%) were able to discontinue the regular use of analgesics. The PSA responders also showed an increase in hemoglobin levels. The change in serum interleukin-6 levels was significantly associated with a response to DXM (P=0.0065). Severe adverse events of DXM were rare. Clinicopathological factors predicting the PSA response to DXM were age, time from initial androgen deprivation therapy to DXM and PSA velocity prior to DXM. In conclusion, oral low-dose DXM led to an acceptable PSA response in patients with AIPC. Thus, this therapy may be an effective and safe alternative for the treatment of AIPC, particularly for patients who are not favourable candidates for chemotherapy.

View Figures

View References

1	Scher HI, Steineck G and Kelly WK: Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 46:142–148. 1995. View Article : Google Scholar : PubMed/NCBI
2	Fakih M, Johnson CS and Trump DL: Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology. 60:553–561. 2002. View Article : Google Scholar : PubMed/NCBI
3	Nishimura K, Nonomura N, Yasunaga Y, et al: Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 89:2570–2576. 2000. View Article : Google Scholar : PubMed/NCBI
4	Zhang C, Mattern J, Haferkamp A, et al: Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther. 5:59–64. 2006. View Article : Google Scholar : PubMed/NCBI
5	Weitzman AL, Shelton G, Zuech N, et al: Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen-independent prostate cancer. J Urol. 163:834–837. 2000. View Article : Google Scholar : PubMed/NCBI
6	Chang CY, Walther PJ and McDonnell DP: Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res. 61:8712–8717. 2001.PubMed/NCBI
7	Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV and Koutsilieris M: Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate. 26:260–269. 1995. View Article : Google Scholar : PubMed/NCBI
8	Gao QZ, Lu JJ, Liu ZD, Zhang H, Wang SM and Xu H: Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression. Asian J Androl. 10:635–641. 2008. View Article : Google Scholar : PubMed/NCBI
9	Akakura K, Akimoto S, Ohki T and Shimazaki J: Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology. 45:700–705. 1995. View Article : Google Scholar
10	Soloway MS, Hardeman SW, Hickey D, et al: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 61:195–202. 1988. View Article : Google Scholar : PubMed/NCBI
11	Lam JS, Leppert JT, Vemulapalli SN, Shvarts O and Belldegrun AS: Secondary hormonal therapy for advanced prostate cancer. J Urol. 175:27–34. 2006. View Article : Google Scholar : PubMed/NCBI
12	Saad F, Gleason DM, Murray R, et al: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 96:879–882. 2004. View Article : Google Scholar
13	Akakura K, Suzuki H, Ueda T, et al: Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate. 56:106–109. 2003. View Article : Google Scholar : PubMed/NCBI
14	Okamoto M, Lee C and Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 57:141–146. 1997.PubMed/NCBI
15	Chung TD, Yu JJ, Spiotto MT, Bartkowski M and Simons JW: Characterization of the role of IL-6 in the progression of prostate cancer. Prostate. 38:199–207. 1999. View Article : Google Scholar : PubMed/NCBI
16	Lou W, Ni Z, Dyer K, Tweardy DJ and Gao AC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate. 42:239–242. 2000. View Article : Google Scholar : PubMed/NCBI
17	Hobisch A, Eder IE, Putz T, et al: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58:4640–4645. 1998.PubMed/NCBI
18	Chen T, Wang LH and Farrar WL: Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 60:2132–2135. 2000.
19	Ueda T, Bruchovsky N and Sadar MD: Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem. 277:7076–7085. 2002. View Article : Google Scholar : PubMed/NCBI
20	Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
21	Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
22	Shimojo M, Hiroi N, Yakushiji F, Ueshiba H, Yamaguchi N and Miyachi Y: Differences in down-regulation of glucocorticoid receptor mRNA by cortisol, prednisolone and dexamethasone in HeLa cells. Endocr J. 42:629–636. 1995. View Article : Google Scholar : PubMed/NCBI
23	Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M and Scher HI: Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol. 13:2208–2213. 1995.PubMed/NCBI
24	Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 17:2506–2513. 1999.PubMed/NCBI
25	Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L and Rider W: Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 7:590–597. 1989.PubMed/NCBI
26	Sartor O, Weinberger M, Moore A, Li A and Figg WD: Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology. 52:252–256. 1998. View Article : Google Scholar : PubMed/NCBI
27	Fuse H, Nozaki T, Fujiuchi Y, Mizuno I, Nagakawa O and Okumura A: Treatment with prednisolone of hormone-refractory prostate cancer. Arch Androl. 52:35–38. 2006. View Article : Google Scholar : PubMed/NCBI
28	Nishiyama T and Terunuma M: Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int J Urol. 5:44–47. 1998. View Article : Google Scholar : PubMed/NCBI